KR20110074611A - 상피 조직의 치료 조성물 - Google Patents

상피 조직의 치료 조성물 Download PDF

Info

Publication number
KR20110074611A
KR20110074611A KR1020117011508A KR20117011508A KR20110074611A KR 20110074611 A KR20110074611 A KR 20110074611A KR 1020117011508 A KR1020117011508 A KR 1020117011508A KR 20117011508 A KR20117011508 A KR 20117011508A KR 20110074611 A KR20110074611 A KR 20110074611A
Authority
KR
South Korea
Prior art keywords
topiramate
pharmaceutical composition
skin
scar
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020117011508A
Other languages
English (en)
Korean (ko)
Inventor
네이선 앤드류 샤피라
아미르 바질라이
Original Assignee
노보더믹스 인터내셔널 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노보더믹스 인터내셔널 리미티드 filed Critical 노보더믹스 인터내셔널 리미티드
Publication of KR20110074611A publication Critical patent/KR20110074611A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020117011508A 2008-10-21 2009-10-21 상피 조직의 치료 조성물 Ceased KR20110074611A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13699408P 2008-10-21 2008-10-21
US61/136,994 2008-10-21

Publications (1)

Publication Number Publication Date
KR20110074611A true KR20110074611A (ko) 2011-06-30

Family

ID=42118987

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117011508A Ceased KR20110074611A (ko) 2008-10-21 2009-10-21 상피 조직의 치료 조성물

Country Status (9)

Country Link
US (1) US20110257257A1 (cg-RX-API-DMAC7.html)
EP (1) EP2361083A4 (cg-RX-API-DMAC7.html)
JP (1) JP2012506417A (cg-RX-API-DMAC7.html)
KR (1) KR20110074611A (cg-RX-API-DMAC7.html)
CN (1) CN102256602A (cg-RX-API-DMAC7.html)
BR (1) BRPI0914454A2 (cg-RX-API-DMAC7.html)
CA (1) CA2741028A1 (cg-RX-API-DMAC7.html)
RU (1) RU2011120054A (cg-RX-API-DMAC7.html)
WO (1) WO2010046861A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150082476A (ko) 2013-02-26 2015-07-15 아사히 가세이 겐자이 가부시키가이샤 페놀 수지 발포판 및 그 제조 방법

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9468599B2 (en) * 2011-12-27 2016-10-18 Cmpd Licensing, Llc Composition and method for compounded therapy
US9962391B2 (en) 2011-12-27 2018-05-08 Cmpd Licensing, Llc Composition and method for compounded therapy
US11213501B2 (en) 2011-12-27 2022-01-04 Cmpd Licensing, Llc Composition and method for compounded therapy
US10813897B2 (en) 2011-12-27 2020-10-27 Cmpd Licensing, Llc Composition and method for compounded therapy
US11213500B2 (en) 2011-12-27 2022-01-04 Cmpd Licensing, Llc Composition and method for compounded therapy
US9933436B2 (en) * 2012-09-07 2018-04-03 Shiseido Company, Ltd. Method of evaluating cellulite and method of evaluating cellulite-effective drug using fibulin-3 and/or sarcoglycan gamma as an indicator
US20240180946A1 (en) * 2021-03-24 2024-06-06 Orgenesis Inc. Compositions comprising topiramate for treating dermatological conditions
CN115245470A (zh) * 2021-04-27 2022-10-28 山东本真化妆品有限公司 水包油乳液及其在对抗婴儿湿疹中的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3784692A (en) * 1967-06-16 1974-01-08 Warner Lambert Co 17-propionate,21-ester derivatives of 6alpha,9alpha-difluoroprednisolone,compositions and use
US4323694A (en) * 1981-04-13 1982-04-06 Finetex, Inc. Benzoic acid esters
US5352442A (en) * 1985-07-18 1994-10-04 Proctor Peter H Topical tempo
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
GB9828620D0 (en) * 1998-12-23 1999-02-17 Glaxo Group Ltd Medicaments
IL137559A (en) * 2000-07-27 2006-12-31 Amnon Sintov A system for administering drugs through the skin
US20020082222A1 (en) * 2000-11-30 2002-06-27 Shapira Nathan Andrew Treatments for neurogenetic disorders, impulse control disorder, and wound healing
FR2829693B1 (fr) * 2001-09-20 2004-02-27 Oreal Creme cosmetique moussante
US6824786B2 (en) * 2001-11-27 2004-11-30 Ruey J. Yu Compositions comprising phenyl-glycine derivatives
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US20040014681A1 (en) * 2002-05-14 2004-01-22 Ralph Ryback Method for treating dermatoses and tissue damage
CA2502986C (en) * 2002-10-25 2011-08-23 Foamix Ltd. Cosmetic and pharmaceutical foam
US20080031907A1 (en) * 2002-10-25 2008-02-07 Foamix Ltd. Cosmetic and pharmaceutical foam
ES2366273T3 (es) * 2003-03-21 2011-10-18 Nexmed Holdings, Inc. Esmalte de uñas antifúngico y procedimiento de utilización.
US6949518B1 (en) * 2003-06-25 2005-09-27 Pao-Hsien Chu Methods for treating macular degeneration with topiramate

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150082476A (ko) 2013-02-26 2015-07-15 아사히 가세이 겐자이 가부시키가이샤 페놀 수지 발포판 및 그 제조 방법
KR20180083962A (ko) 2013-02-26 2018-07-23 아사히 가세이 겐자이 가부시키가이샤 페놀 수지 발포판 및 그 제조 방법
KR20210027544A (ko) 2013-02-26 2021-03-10 아사히 가세이 겐자이 가부시키가이샤 페놀 수지 발포판 및 그 제조 방법

Also Published As

Publication number Publication date
BRPI0914454A2 (pt) 2015-10-27
EP2361083A4 (en) 2013-11-20
RU2011120054A (ru) 2012-11-27
JP2012506417A (ja) 2012-03-15
EP2361083A1 (en) 2011-08-31
CA2741028A1 (en) 2010-04-29
WO2010046861A1 (en) 2010-04-29
US20110257257A1 (en) 2011-10-20
CN102256602A (zh) 2011-11-23

Similar Documents

Publication Publication Date Title
KR20110074611A (ko) 상피 조직의 치료 조성물
JP6566531B2 (ja) 脂肪組織の減少
Almeida et al. Pluronic® F-127 and Pluronic Lecithin Organogel (PLO): Main features and their applications in topical and transdermal administration of drugs
CA3056395C (en) Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes
US11918691B2 (en) Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
TW201210601A (en) Compounds and methods for skin repair
CA3093459A1 (en) Methods for isolating tumor-specific immune cells from a subject for adoptive cell therapy and cancer vaccines
US20140315991A1 (en) Composition for treatment of epithelial tissue
WO2014190182A1 (en) Topical scar treatment composition and method of using same
HK40014982A (en) Reduction of adipose tissue
HK40014982B (en) Reduction of adipose tissue
WO2013110756A1 (en) Ingenol mebutate in combination with cryotherapy for the treatment of actinic keratosis
JP2021518362A (ja) タキサンのナノ粒子を用いる子宮頸部上皮内腫瘍（ｃｉｎ）および子宮頸癌の処置のための局所療法
Eyelids et al. REVIEW OF RELEVANT LITERATURE

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110520

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20141016

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160107

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20160401

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160107

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I